BA.4.6 seems to be even better at evading our immune response than BA.5.
Articles on omicron BA.4
Displaying all articles
Early on, public health messaging focused on the need for vaccines to combat COVID-19. But far less attention has been given to the role of boosters in preventing deaths and reducing inequities.
We published an article earlier this month that contained incorrect estimates for the basic reproduction number (R0) for COVID subvariants BA.4/BA.5 and BA.2. We have now corrected the error, but I wanted…
A combination of seasonal factors, under-diagnosis and under-reporting could explain why rates of COVID hospitalisation and death are rising faster than cases.
BA.4 and BA.5 are more transmissible than previous variants and subvariants, and are better able to evade immunity from vaccines and previous infections. Here’s what we know about them so far.
Omicron variants BA.4 and BA.5 are behind an increasing wave of infections in the UK. So what happens now?
At this stage of the pandemic complacency is likely to lead to an increase in cases, hospitalisation, morbidity and mortality.
Repeated resurgences of SARS-CoV-2 transmission are expected in the years to come.
With the relaxation of mask-wearing mandates, there’s even more need to know how much over-the-counter tests help.
Top contributors
-
Professor of Biostatistics and Epidemiology, Adelaide University
-
Assistant Professor of Global Health, Boston University
-
Associate Professor of Molecular Medicine, UMass Chan Medical School
-
Director: Modelling and Simulation Hub, Africa (MASHA), University of Cape Town
-
Director: SACEMA, South African Centre for Epidemiological Modelling & Analysis (SACEMA)
-
Research Assistant in the Department of Global Health, Boston University
-
Senior Lecturer, Medical Microbiology, University of Westminster
-
Assistant Professor of Sociology, University of Minnesota
-
Assistant Professor of Medicine, UMass Chan Medical School
-
Research Fellow in Global Health, Boston University
-
Adjunct Professor: Department Internal Medicine, University of Pretoria
-
Principal Researcher - Epidemiology, Wits-VIDA, University of the Witwatersrand
-
Senior Research Fellow in the Sheffield Alcohol Research Group, University of Sheffield